Nanobiotix enters September with a subdued but slightly accelerating slide — down 6.3% on the week to €33.50 — as the company heads toward a September 18 earnings event with a lending market that has just shifted meaningfully in the space of a few days.
The most striking move this week has nothing to do with the share price itself: it is what has happened to borrow availability. After running extraordinarily loose for months — availability was above 6,000% as recently as late August, meaning roughly sixty lendable shares for every one borrowed — it has tightened sharply to around 1,676% by September 1. That is still well within the "normal-to-loose" range and not a sign of any squeeze pressure, but the move is notable for its speed: availability more than halved in less than a week. Cost to borrow has edged up in tandem, now at 8.5% after touching its lowest level of the past month on August 20. Borrow costs peaked above 10.5% in late July and early August, so the current level is not extreme — but the direction has reversed. Short interest itself remains negligible at roughly 0.1% of the free float, which means there is no meaningful short-side story here. The lending market is still very loose; the shift is worth tracking, not alarming.
What is more relevant to the stock's direction is where the institutional register sits. Johnson & Johnson Innovation — JJDC — holds 11.6% and has not moved. Artal Group trimmed its position by 1.36 million shares in Q2, leaving it at 9.2%. Qatar Holding similarly reduced by roughly 766,000 shares to 7.3% of shares. Goldman Sachs added 462,000 shares to reach 5.9% as of August 21 — the most recent reported change from a financially-oriented holder — while Capital Research added 686,000 shares across the quarter to reach 4.2%. The picture that emerges is one of financial investors selectively adding while two of the larger strategic-ish holders reduced exposure.
The broader scoring backdrop is modestly cautious. The ORTEX short score has drifted upward from 32.7 on August 21 to 35.2 by September 1 — not a dramatic move, but a sustained grind higher over ten days that is worth monitoring ahead of the September 18 print. EPS momentum is negative on both a 30-day and 90-day view, ranking in the 34th and 28th percentiles respectively. EPS surprise history is weak, in the 7th percentile — Nanobiotix has a consistent track record of missing estimates. Analyst data has grown stale (last updated in early June, now more than 90 days ago), so a consensus target of €47.80 should be treated as directional rather than precise given the stock's current position at €33.50; citing the gap is valid, but the exact figure should carry a caveat. Forward EPS estimate revisions over twelve months rank in the 73rd percentile, the one score that tilts constructive.
Recent earnings history adds texture ahead of the September 18 event. The April 2 release produced the sharpest single-day move in the dataset, falling 11.5% and extending to nearly -11.3% over five days. The June 5 result was much calmer, down just 1.6% on the day. Prior to that, two consecutive prints in late March 2026 produced positive initial reactions of 6.0% and 7.4% respectively, though the five-day drift faded or reversed both times. The pattern is inconsistent enough that the market does not appear to have a strong directional bias into results — outcomes have swung widely in both directions within a single quarter.
Among correlated peers, RNAC on Nasdaq fell 10.4% on the week and NAMS dropped 8.9%, suggesting weakness across smaller biotech names is not unique to NANO this week. ALCLS on Euronext Paris, the closest geographic and sector comparable, fell around 3.0% — in line with NANO's performance rather than sharply diverging from it.
The September 18 earnings release is the immediate focal point: whether the availability compression seen this week continues, and whether the short score resumes its recent grind, will be worth watching in the two weeks leading up to the print.
See the live data behind this article on ORTEX.
Open NANO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
